Josh Riggs - Feb 24, 2023 Form 4 Insider Report for Oncocyte Corp (OCX)

Role
CEO
Signature
/s/ Josh Riggs
Stock symbol
OCX
Transactions as of
Feb 24, 2023
Transactions value $
$0
Form type
4
Date filed
2/28/2023, 04:59 PM
Previous filing
Jan 19, 2023
Next filing
Jun 13, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCX Option to Purchase Common Stock Award $0 +116K $0.00 116K Feb 24, 2023 Common Stock 116K $0.39 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One third of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 24 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date.